Children's Hospital of Philadelphia and St. Jude Researchers Find Genetic Ancestry Influences How Gene Mutations Impact Cancer Prognosis in Patients With T-cell Acute Lymphoblastic Leukemia
PHILADELPHIA and MEMPHIS, Tenn., June 24, 2025 /PRNewswire/ -- Investigators at Children's Hospital of Philadelphia (CHOP), St. Jude Children's Research Hospital (St. Jude), Dana Farber Cancer Institute (DFCI), and the Children's Oncology Group (COG), unveiled for the first time that changes in certain genes affect an aggressive cancer, T-cell acute lymphoblastic leukemia (T-ALL), differently depending on genetic ancestry. The collaborative study, published recently in the journal Blood Cancer Discovery, further reinforces the critical role of personalized medicine in advancing the treatment of pediatric cancers such as T-ALL.
Most children in the U.S. newly diagnosed with cancer are treated through clinical trials or with regimens established by earlier trial findings. Increasingly, these frontline trials use prognostic biomarkers to guide treatments related to whether patients have high risk or low risk disease. While previous studies found that genetic ancestry affects how certain gene changes appear in cancer, researchers can now show that these gene changes may also predict outcomes differently depending upon an individual's ancestry.
'Our research demonstrates it is essential to ensure the equitable implementation of genomic biomarkers in treatment decisions or we may introduce disparities,' said David T. Teachey, MD, a lead study author at CHOP and Chair of the Acute Lymphoblastic Leukemia Disease Committee in the COG. 'Without this critical step, we risk misclassifying patients into the incorrect high- or low-risk groups, potentially causing undertreatment and increased risk of relapse, or overtreatment and unnecessary side effects, especially in populations of non-European descent.'
Study participants were enrolled in the COG's multicenter phase 3 randomized clinical trial AALL0434 (NCT04408005) conducted from 2007 to 2014. Of the eligible participants evaluable with T-ALL, researchers analyzed complete sequencing for 1,309 individuals included in this study. They found that 80% had mutations in genes where prognostic impact varied depending on their genetic ancestry. For example, a gene called NOTCH1 was linked to better survival in patients of European ancestry but was not associated with better survival in patients of African ancestry. Importantly, this collaborative study brought together experts in the diagnosis and treatment of T-ALL, leukemia genomics, genetic ancestry and social determinants of health research, including study co-author Kira Bona, MD, MPH from DFCI.
'The study provides another important example of the way in which heritable and tumor-acquired genetic variations interact to determine the features and behavior of leukemia,' said study author Charles Mullighan, MBBS (Hons), MSc, MD, Senior Deputy Director of the St. Jude Comprehensive Cancer Center.
The study evaluated tools that group patients into risk categories. One method worked well for everyone, no matter their ancestry. But another tool used, developed mainly from European data, sometimes gave misleading results for people from backgrounds other than European ancestry. The researchers also emphasized that certain genetic ancestries may be associated with more aggressive disease forms or different responses to treatment.
'Our groups have a long-standing interest in how genetic ancestry affects cancer biology in children. This study is another example of the fruitful collaboration with COG that led to the discovery of new genetic basis of racial/ethnic differences in leukemia,' said co-corresponding author Jun J. Yang, PhD, Endowed Chair in Pharmacogenomics of the St. Jude Department of Pharmacy and Pharmaceutical Sciences.
'The lessons learned from this work should be investigated in other types of cancer in children and adults to improve outcomes for patients of all ancestral backgrounds,' said first author Haley M. Newman, MD, a junior faculty member at CHOP.
The research was supported by K12CA076931-24, Gabriella Miller Kids First (X01HD100702), R03CA256550, Alex's Lemonade Stand Foundation, the Leukemia and Lymphoma Society, Singapore NMRC, Singapore NUHS NCSP, Hyundai Hope on Wheels, (R01CA193776),(U10CA180886), (R01CA264837), (U24CA114766), (U24CA196173), (U10CA180899, St.Baldricks Research Foundation, Pennsylvania Department of Health, the Harrison Willing Memorial Research Fund, The Invisible Prince Foundation, the Aiden Everett Davies Innovation Fund, ALSAC the fundraising and awareness organization of St. Jude, The St. Jude Chromatin Collaborative, (P30CA021765), (R35CA197695), (U54CA243124) and the Canadian Institute for Health Research.
Newman et al. 'Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia.' Blood Cancer Discov. Online May 28, 2025. DOI: 10.1158/2643-3230.BCD-25-0049.
About Children's Hospital of Philadelphia:
A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.
About St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit stjude.org, read St. Jude Progress a digital magazine, and follow St. Jude on social media at @stjuderesearch.
Contact: Jennifer Lee
Children's Hospital of Philadelphia
(267) 426-6084
[email protected]
Contact: Michael Sheffield
St. Jude Children's Research Hospital
(901) 379-6072
[email protected]
[email protected]
View original content: https://www.prnewswire.com/news-releases/childrens-hospital-of-philadelphia-and-st-jude-researchers-find-genetic-ancestry-influences-how-gene-mutations-impact-cancer-prognosis-in-patients-with-t-cell-acute-lymphoblastic-leukemia-302488717.html
SOURCE Children's Hospital of Philadelphia
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
FDA sends warning to 5 sunscreen brands including Supergoop — why they could be pulled from shelves
Some of the summer's hottest beauty products just got burned. 'Beware of sunscreen products in mousse form because they might not be effective,' the Food and Drug Administration cautioned in a post on X this week. The alert follows a wave of warning letters the agency sent to Supergoop!, Vacation Inc. and three other popular brands, accusing them of peddling whipped, mousse and foam sunscreens that flout federal laws. Advertisement 3 Mousse sunscreen may be popular, but the FDA says the product doesn't comply with federal laws regarding over-the-counter drugs. Supergoop! Before you send your beloved sunscreens packing, let's break down the FDA's warnings. The letters — also sent to Kalani Sunwear, K & Care Organics and Fallien Cosmeceuticals (makers of TiZo sunscreen) — claim the frothy formulas are 'misbranded.' That's because sunscreens are classified as over-the-counter drugs in the US — and that comes with strict regulations around how they're formulated and marketed. Advertisement Per FDA rules, sunscreens can only be sold as oils, lotions, creams, gels, butters, pastes, ointments, sticks, sprays or powders — not foams, mousses, or whips. To use those formats legally, companies must submit a new drug application with sufficient data proving their safety and effectiveness. 'There are no FDA-approved applications in effect for your drug products,' the agency wrote. Advertisement 3 Because they're marketed to prevent sunburns and skin cancer, sunscreens are regulated as drugs. Vacation The FDA also took aim at Vacation Inc.'s 'Classic Whip Sunscreen,' sold in containers that look like whipped cream cans and advertised as 'dessert for your skin.' 'Packaging drug products in containers that resemble food containers commonly used by adults and children can mislead consumers into mistaking the products for food, which is of particular concern as this increases the risk of accidental ingestion,' the agency warned. Advertisement But the FDA's heat doesn't necessarily mean these fluffy formulas fall short at blocking burns or reducing skin cancer risk. 'The letter does not state that mousse-format sunscreens are less effective or unsafe, nor does it question the quality or performance of our formulation,' Kalani Sunwear told Cosmetics Business, adding that it's 'Sun Mousse SPF 50 is developed and manufactured in Sweden to the highest European standards.' A Supergoop! spokesperson told The Post that the warning 'is focused on product labeling and has nothing to do with its safety, effectiveness or formula,' and added that the company is 'working closely with the FDA to resolve this matter.' 3 To legally sell sunscreens in mousse, foam, or whipped form, companies have to file new drug applications, the FDA said. TikTok/supergoop Still, some outside experts aren't so sure about the whipped format. 'SPF is determined by applying 2 mg/cm^2, which is measured by weight, not volume,' Ava Perkins, a cosmetic chemist and US sunscreen expert, told The Cut. 'Because these mousse sunscreens have so much air incorporated into the product, it can be challenging to know if you're putting on enough, even if it seems like a lot is being dispensed,' she added. Advertisement The FDA's letters, dated August 6, gave each company 15 working days to explain how they plan to fix the issues or prove they're not in violation. Kalani Sunwear has already started taking action, temporarily pulling its mousse-format sunscreen from its US website 'to ensure full compliance with the regulations,' according to CBS News. The Post has reached out to Vacation, Kalani Sunwear, K & Care Organics and Fallien Cosmeceuticals for comment.
4 hours ago
Ethiopian fossil Lucy leaves for her first exhibition in Europe
ADDIS ABABA, Ethiopia -- The human ancestor fossil known as Lucy left Ethiopia for display in a European museum, Ethiopian national media reported Friday, citing Tourism Minister Selamawit Kassa. Lucy's skeleton, which is 40% complete, left Ethiopia on Friday and will be displayed at the Czech National Museum in Prague for approximately two months. Lucy was recovered in Ethiopia in 1974 from what was an ancient lake near fossilized remains of crocodiles, turtle eggs and crab claws. She was a member of Australopithecus afarensis, an early human species that lived in Africa between about 4 million and 3 million years ago. This is the second time Lucy has left Ethiopia. The first was in 2013, when she toured the United States. Lucy's fragmented bones will be exhibited alongside Selam, the fossil of an Australopithecus baby that is about 100,000 years older than Lucy and was discovered in the same region 25 years later. 'As an iconic specimen, she belongs to the whole world, so sharing her with the rest of humanity is something that everyone would love to see,' said Yohannes Haile-Selassie, Director of the Institute of Human Origins at Arizona State University. While many experts believe Lucy's trip to Europe presents a once-in-a-lifetime opportunity for people in Europe and beyond, there are safety concerns about the transportation of her fragile bones. 'The fragmented bones of Lucy are truly unique and need utmost care. Traveling to Europe has its own risks,' said Gidey Gebreegziabher, an archaeologist and Ph.D. candidate at the University of Warsaw, Poland, 'She will also be exposed to different climate conditions, which could potentially have negative impacts on her preservation.' Even in Ethiopia, the public has only occasionally seen the real Lucy fossil. At the National Museum of Ethiopia, a replica of Lucy is exhibited while the actual remains are stored in a secure vault. 'I've seen how she was packed, so I have no worries about anything happening to Lucy anymore,' Yohannes said. Lucy's quiet departure on Thursday night also raises questions about transparency as many Ethiopians —who take pride in her — were unaware of her journey to Europe. 'It's unbelievable! The government appears to be deliberately sidelining its people from the narrative of their own heritage,' Gebreegziabher said. Bekele Reta, 43, a resident who lives just 50 meters (164 feet) from the museum where Lucy is housed, was unaware of Lucy's departure until he saw it on social media. 'I learned this morning on Facebook that Lucy has departed for Prague. It's unfortunate that most Ethiopians only have the opportunity to see her showcased elsewhere.' he said. Early this year, the director general of the Czech National Museum, Michal Lukeš, in a statement announcing the exhibition of Lucy and Selam, expressed his appreciation of the Ethiopians for agreeing to 'lend' the remains. 'These priceless exhibits give us a unique insight into the past and deepen our understanding of humanity's roots,' said Lukeš.
Los Angeles Times
15 hours ago
- Los Angeles Times
Judge orders RFK Jr.'s health department to stop sharing Medicaid data with deportation officials
WASHINGTON — A federal judge ordered the nation's health department to stop giving deportation officials access to the personal information — including home addresses — of all 79 million Medicaid enrollees. The U.S. Department of Health and Human Services first handed over the personal data on millions of Medicaid enrollees in a handful of states in June. After an Associated Press report identified the new policy, 20 states filed a lawsuit to stop its implementation. In July, the Centers for Medicare and Medicaid Services entered into a new agreement that gave the Department of Homeland Security daily access to view the personal data — including Social Security numbers and home address — of all the nation's 79 million Medicaid enrollees. Neither agreement was announced publicly. The extraordinary disclosure of such personal health data to deportation officials in the Trump administration's far-reaching immigration crackdown immediately prompted the lawsuit over privacy concerns. The Medicaid data sharing is part of a broader effort by the Trump administration to provide DHS with more data on migrants. In May, for example, a federal judge refused to block the Internal Revenue Service from sharing immigrants' tax data with Immigration and Customs Enforcement to help agents locate and detain people living without legal status in the U.S. The order, issued by federal Judge Vince Chhabria in California, temporarily halts the health department from sharing personal data of enrollees in those 20 states, which include California, Arizona, Washington and New York. 'Using CMS data for immigration enforcement threatens to significantly disrupt the operation of Medicaid—a program that Congress has deemed critical for the provision of health coverage to the nation's most vulnerable residents,' Chhabria wrote in his decision, issued on Tuesday. Chhabria, an appointee of President Barack Obama, said that the order will remain in effect until the health department outlines 'reasoned decisionmaking' for its new policy of sharing data with deportation officials. A spokesperson for the federal health department declined to directly answer whether the agency would stop sharing its data with DHS. HHS has maintained that its agreement with DHS is legal. Immigrants who are not living in the U.S. legally, as well as some lawfully present immigrants, are not allowed to enroll in the Medicaid program that provides nearly free coverage for health services. But federal law requires all states to offer emergency Medicaid, a temporary coverage that pays only for lifesaving services in emergency rooms to anyone, including non-U.S. citizens. Medicaid is a jointly funded program between states and the federal government. Immigration advocates have said the disclosure of personal data could cause alarm among people seeking emergency medical help for themselves or their children. Other efforts to crack down on illegal immigration have made schools, churches, courthouses and other everyday places feel perilous to immigrants and even U.S. citizens who fear getting caught up in a raid. 'Protecting people's private health information is vitally important,' Washington state's Attorney General Nick Brown said in a statement. 'And everyone should be able to seek medical care without fear of what the federal government may do with that information.' Seitz and Kindy write for the Associated Press.
